Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–61. https://doi.org/10.1002/hec.3633.

Article  PubMed  Google Scholar 

Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoecon. 2018;36:509–22. https://doi.org/10.1007/s40273-017-0606-1.

Article  Google Scholar 

Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008. https://doi.org/10.1586/14737167.8.2.165.

Article  PubMed  Google Scholar 

Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–35. https://doi.org/10.1016/j.jval.2016.02.017.

Article  PubMed  PubMed Central  Google Scholar 

Kniesner TJ, Viscusi WK. The value of a statistical life. Forthcoming, Oxford Research Encyclopedia of Economics and Finance. Vanderbilt Law Research Paper No. 19–15. 2019. https://doi.org/10.2139/ssrn.3379967.

Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4(5):485–504. https://doi.org/10.2217/cer.15.38.

Article  PubMed  Google Scholar 

Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–5. https://doi.org/10.1093/heapol/czw096.

Article  PubMed  Google Scholar 

Baker R, Chilton S, Donaldson C, Jones-Lee M, Lancsar E, Mason H, et al. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Econ Policy Law. 2011;6(4):435–47. https://doi.org/10.1017/S1744133111000181.

Article  PubMed  Google Scholar 

Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog VT, Brouwer WB. Severity-adjusted probability of being cost effective. Pharmacoecon. 2019;37:1155–63. https://doi.org/10.1007/s40273-019-00810-8.

Article  Google Scholar 

Toumi M, Rémuzat C, El Hammi E, Millier A, Aballéa S, Chouaid C, et al. Current process and future path for health economic assessment of pharmaceuticals in France. J Mark Access Health Policy. 2015;3(1):27902. https://doi.org/10.3402/jmahp.v3.27902.

Article  Google Scholar 

Fasseeh A, Karam R, Jameleddine M, George M, Kristensen FB, Al-Rabayah AA, et al. Implementation of health technology assessment in the Middle East and North Africa: comparison between the current and preferred status. Front Pharmacol. 2020;11:15. https://doi.org/10.3389/fphar.2020.00015.

Article  PubMed  PubMed Central  Google Scholar 

Elsisi GH, Kaló Z, Eldessouki R, Elmahdawy MD, Saad A, Ragab S, et al. Recommendations for reporting pharmacoeconomic evaluations in Egypt. Value Health Reg Issues. 2013;2(2):319–27. https://doi.org/10.1016/j.vhri.2013.06.014.

Article  PubMed  Google Scholar 

Fasseeh AN, Elezbawy B, Gamal M, Seyam A, Abourawash A, George M, et al. A roadmap toward implementing health technology assessment in Egypt. Front Public Health. 2022;10:896175. https://doi.org/10.3389/fpubh.2022.896175.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization (WHO). HTA agencies and networks by member states. 2014. https://cdn.who.int/media/docs/default-source/medical-devices/health-technology-assessment/hta-agencies-and-networks-by-member-states---august-2014.pdf?sfvrsn=32df2d3f_3. Accessed 22 Aug 2021.

The European Network for Health Technology Assessment EUnetHTA. EUnetHTA Network. 2021. https://www.eunethta.eu/about-eunethta/eunethtanetwork/. Accessed 22 Aug 2021.

The International Network of Agencies for Health Technology Assessment (INAHTA). INAHTA members list. https://www.inahta.org/members/members_list/. Accessed 22 Aug 2021.

International Society for Pharmacoeconomics and Outcomes Research ISPOR. Pharmacoeconomic guidelines around the world. https://www.ispor.org/heor-resources/more-heor-resources/pharmacoeconomic-guidelines/pe-guideline-detail. Accessed 22 Aug 2021.

Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):239–42. https://doi.org/10.1080/14737167.2017.1330152.

Article  PubMed  Google Scholar 

The World Bank. GDP per capita (current US$). https://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 23 Aug 2021.

Knoema. Taiwan province of China - gross domestic product per capita in current prices. https://knoema.com/atlas/Taiwan-Province-of-China/GDP-per-capita. Accessed 23 Aug 2021.

Knoema. Bhutan - gross domestic product per capita in current prices. https://knoema.com/atlas/Bhutan/GDP-per-capita. Accessed 23 Aug 2021.

Knoema. GDP per capita in Cuba. https://knoema.com/data/cuba+gdp+per-capita?unit=current-prices%20us-dollars. Accessed 23 Aug 2021.

The World Bank. Official exchange rate (LCU per US$, period average). https://data.worldbank.org/indicator/PA.NUS.FCRF. Accessed 23 Aug 2021.

The World Bank. World Bank Country and Lending Groups. 2019. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 23 Aug 2021.

Institute for Quality and Efficiency in Health Care. General methods for the assessment of the relation of benefits to costs. 2009. https://www.iqwig.de/methoden/general_methods_for_the_assessment_of_the_rela.pdf. Accessed 23 Aug 2021.

Tatar M, Tuna E, Caglayan B, Sarica N, Firidin A. Cost effectiveness of sodium oxybate in treatment of cataplexy in patients with narcolepsy in Turkey. Value Health. 2015;18(7):A757. https://doi.org/10.1016/j.jval.2015.09.2465.

Article  Google Scholar 

Culig J, Antolic S, Szkultecka-Dębek M. Drug policy in Croatia. Value Health Reg Issues. 2017;13:27–30. https://doi.org/10.1016/j.vhri.2017.07.005.

Article  PubMed  Google Scholar 

PHARMAC. Sensitivity analysis. 2020. https://pharmac.govt.nz/assets/Sensitivity-Analysis-2074.pdf. Accessed 23 Aug 2021.

Parada CV, Veerman JL. Cost-effectiveness study of HPV vaccination as a primary prevention strategy for anal cancer in HIV-positive men in Chile. Value Health Reg Issues. 2016;11:17–23. https://doi.org/10.1016/j.vhri.2015.12.002.

Article  Google Scholar 

Ornstova E, Sebestianova M, Mlcoch T, Lamblova K, Dolezal T. Highly innovative drug program in the Czech Republic: description and pharmacoeconomic results—cost-effectiveness and budget impact analyses. Value Health Reg Issues. 2018;16:92–8. https://doi.org/10.1016/j.vhri.2018.08.003.

Article  PubMed  Google Scholar 

Nagyjánosi l. Professional healthcare guideline on the methodology of health technology assessment. ISPOR. 2017. https://www.ispor.org/heor-resources/more-heor-resources/pharmacoeconomic-guidelines/pe-guideline-detail/hungary. Accessed 20 Aug 2021.

Health Information and Quality Authority. Guidelines for the retrieval and interpretation of economic evaluations of health technologies in Ireland. 2014. https://www.hiqa.ie/sites/default/files/2017-01/Guidelines-Retrieval-and-Interpretation-of-Econ-Lit.pdf. Accessed 22 Aug 2021.

Zorginstituut Nederland. Cost-effectiveness in practice. 2015. https://english.zorginstituutnederland.nl/publications/reports/2015/06/16/cost-effectiveness-in-practice. Accessed 22 Aug 2021.

Markiewicz O. Value of life year and cost-effectiveness thresholds: the case of Poland. Cent Eur Econ J. 2021;8(55):256–68. https://doi.org/10.2478/ceej-2021-0019.

Article  Google Scholar 

Perelman J, Soares M, Mateus C, Duarte A, Faria R, Ferreira L, et al. Methodological guidelines for economic evaluation studies. 2019. https://www.infarmed.pt/documents/15786/4001413/Orienta%C3%A7%C3%B5es+metodol%C3%B3gicas+para+estudos+de+avalia%C3%A7%C3%A3o+econ%C3%B3mica+de+tecnologias+de+sa%C3%BAde+%28EN%29/ebcfd930-94e2-c7e1-100a-ee1df3d76882.

Tesar T, Obsitnik B, Kaló Z, Kristensen FB. How changes in reimbursement practices influence the financial sustainability of medicine policy: lessons learned from Slovakia. Front Pharmacol. 2019;10:664. https://doi.org/10.3389/fphar.2019.00664.

Article  PubMed  PubMed Central  Google Scholar 

Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open. 2015;5(10):e008123. https://doi.org/10.1136/bmjopen-2015-008123.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence (NICE). Cost-effectiveness analysis: treatment initiation threshold for people with stage 1 hypertension. 2019. https://www.nice.org.uk/guidance/ng136/evidence/costeffectiveness-analysis-treatment-initiation-threshold-for-people-with-stage-1-hypertension-pdf-6957345277. Accessed 20 Aug 2021.

Ananthapavan J, Nguyen PK, Bowe SJ, Sacks G, Herrera AMM, Swinburn B, et al. Cost-effectiveness of community-based childhood obesity prevention interventions in Australia. Int J Obs. 2019;43(5):1102–12. https://doi.org/10.1038/s41366-019-0341-0.

Article  Google Scholar 

Simoens S, Bento-Abreu A, Merckx B, Joubert S, Vermeersch S, Pavelyev A, et al. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent human papillomavirus vaccine in Belgium. Front Pharmacol. 2021;12:628434. https://doi.org/10.3389/fphar.2021.628434.

Article  PubMed  PubMed Central  Google Scholar 

Ubels J, Sable C, Beaton AZ, Nunes MCP, Oliveira KK, Rabelo LC, et al. Cost-effectiveness of rheumatic heart disease echocardiographic screening in Brazil: data from the PROVAR+ study: cost-effectiveness of RHD screening in Brazil. Glob Heart. 2020;15(1):18. https://doi.org/10.5334/gh.529.

Article  PubMed  PubMed Central  Google Scholar 

The Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH. Guidelines for the economic evaluation of health technologies: Canada. 2017. https://www.cadth.ca/sites/default/files/pdf/economic_guidelines_worked_example.pdf. Accessed 20 Aug 2021.

Canaway A, Pincus T, Underwood M, Shapiro Y, Chodick G, Ben-Ami N. Is an enhanced behaviour change intervention cost-effective compared with physiotherapy for patients with chronic low back pain? Results from a multicentre trial in Israel. BMJ Open. 2018;8(4):e019928. https://doi.org/10.1136/bmjopen-2017-019928.

Article  PubMed  PubMed Central  Google Scholar 

Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Hum Vaccin Immunother. 2018;14(8):1867–73.